IO Biotech, Inc.
IOBT
Price:
$1.21
Market Cap:
$79.72M
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was i...[Read more]
Industry
Biotechnology
IPO Date
2021-11-05
Stock Exchange
NASDAQ
Ticker
IOBT
The ROE as of September 2024 (TTM) for IO Biotech, Inc. (IOBT) is -70.05%
According to IO Biotech, Inc.’s latest financial reports and current stock price. The company's current ROE is -70.05%. This represents a change of 290.51% compared to the average of -17.94% of the last 4 quarters.
IO Biotech, Inc. (IOBT) Historical ROE (quarterly & annually)
How has IOBT ROE performed in the past?
The mean historical ROE of IO Biotech, Inc. over the last ten years is -13.65%. The current -70.05% ROE has changed 413.04% with respect to the historical average. Over the past ten years (40 quarters), IOBT's ROE was at its highest in in the March 2020 quarter at 238.65%. The ROE was at its lowest in in the March 2021 quarter at -143.99%.
Average
-13.65%
Median
-32.03%
Minimum
-64.65%
Maximum
45.68%
IO Biotech, Inc. (IOBT) ROE by Quarter and Year
Discovering the peaks and valleys of IO Biotech, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 60.67%
Maximum Annual ROE = 45.68%
Minimum Annual Increase = -193.70%
Minimum Annual ROE = -64.65%
| Year | ROE | Change |
|---|---|---|
| 2023 | -64.65% | 25.62% |
| 2022 | -51.46% | 60.67% |
| 2021 | -32.03% | -193.70% |
| 2020 | 34.18% | -25.17% |
IO Biotech, Inc. (IOBT) Average ROE
How has IOBT ROE performed in the past?
The current ROE of IO Biotech, Inc. (IOBT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-49.38%
5-year avg
-13.65%
10-year avg
-13.65%
IO Biotech, Inc. (IOBT) ROE vs. Peers
How is IOBT’s ROE compared to its peers?
IO Biotech, Inc.’s ROE is greater than PMV Pharmaceuticals, Inc. (-21.96%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than MediciNova, Inc. (-13.37%), greater than Pharvaris N.V. (-36.89%), greater than PepGen Inc. (-62.74%), greater than Pardes Biosciences, Inc. (-54.84%), greater than Shattuck Labs, Inc. (-68.65%), less than Champions Oncology, Inc. (323.52%), greater than Century Therapeutics, Inc. (-65.37%), greater than Structure Therapeutics Inc. (-20.15%), greater than Erasca, Inc. (-131.94%), less than ASLAN Pharmaceuticals Limited (543.83%), greater than Lyra Therapeutics, Inc. (-143.74%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than NewAmsterdam Pharma Company N.V. (-86.66%), less than Inventiva S.A. (550.46%), greater than Cullinan Oncology, Inc. (-28.37%), greater than Compass Therapeutics, Inc. (-28.67%), greater than Design Therapeutics, Inc. (-18.48%), greater than Werewolf Therapeutics, Inc. (-48.25%), greater than Ikena Oncology, Inc. (-42.81%), greater than Stoke Therapeutics, Inc. (-57.89%),
| Company | ROE | Market cap |
|---|---|---|
| -21.96% | $79.34M | |
| -47.03% | $556.93M | |
| -13.37% | $80.93M | |
| -36.89% | $1.11B | |
| -62.74% | $321.99M | |
| -54.84% | $135.19M | |
| -68.65% | $180.89M | |
| 323.52% | $63.75M | |
| -65.37% | $146.56M | |
| -20.15% | $2.28B | |
| -131.94% | $834.80M | |
| 543.83% | $1.70M | |
| -143.74% | $18.33M | |
| -70.40% | $377.14M | |
| -86.66% | $1.49B | |
| 550.46% | $119.08M | |
| -28.37% | $1.02B | |
| -28.67% | $244.91M | |
| -18.48% | $330.10M | |
| -48.25% | $106.20M | |
| -42.81% | $80.59M | |
| -57.89% | $836.57M |
Build a custom stock screener for IO Biotech, Inc. (IOBT) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like IO Biotech, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
IO Biotech, Inc. (IOBT) and other stocks custom spreadsheet templates
The easiest way to analyze a company like IO Biotech, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is IO Biotech, Inc.'s ROE?
How is the ROE calculated for IO Biotech, Inc. (IOBT)?
What is the highest ROE for IO Biotech, Inc. (IOBT)?
What is the 3-year average ROE for IO Biotech, Inc. (IOBT)?
What is the 5-year average ROE for IO Biotech, Inc. (IOBT)?
How does the current ROE for IO Biotech, Inc. (IOBT) compare to its historical average?